Aripiprazole lauroxil
Abilify, Aripiprazole, Aristada (aripiprazole lauroxil) is a small molecule pharmaceutical. Aripiprazole lauroxil was first approved as Abilify on 2004-06-04. It is used to treat schizophrenia and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat bipolar disorder and schizophrenia. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 6, D(4) dopamine receptor, 5-hydroxytryptamine receptor 7, histamine H1 receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 1B, and 5-hydroxytryptamine receptor 1D.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Aristada
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| abilify | New Drug Application | 2024-07-17 |
| abilify abilify | New Drug Application | 2013-08-13 |
| abilify abilify discmelt | 2008-08-28 | |
| abilify asimtufii | New Drug Application | 2024-01-30 |
| abilify maintena | New Drug Application | 2024-02-13 |
| abilify maintena kit | New Drug Application | 2013-04-02 |
| abilify mycite | New Drug Application | 2024-11-22 |
| aripiprazole | ANDA | 2024-12-30 |
| aripiprazole oral solution | ANDA | 2016-08-31 |
| aristada | New Drug Application | 2023-12-01 |
Show 2 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| schizophrenia | EFO_0000692 | D012559 | F20 |
| schizophrenia spectrum and other psychotic disorders | — | D019967 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Aripiprazole Lauroxil, Aristada, Alkermes Inc | |||
| 11273158 | 2039-04-06 | U-543 | |
| 9452131 | 2035-03-19 | U-2402 | |
| 9526726 | 2035-03-19 | DP | |
| 10238651 | 2035-03-19 | U-2402 | |
| 10813928 | 2035-03-19 | U-2402, U-2983 | |
| 11406632 | 2035-03-19 | U-2402 | |
| 9193685 | 2033-10-24 | DP | U-543 |
| 11097006 | 2033-10-24 | DP | U-764 |
| 9034867 | 2032-11-07 | DP | U-543 |
| 10226458 | 2032-03-19 | U-543 | |
| 8431576 | 2030-10-26 | DP | |
| 8796276 | 2030-06-24 | U-543 | |
| 10112903 | 2030-06-24 | DP | U-543 |
| Aripiprazole Lauroxil, Aristada Initio Kit, Alkermes Inc | |||
| 10016415 | 2035-09-08 | DP | |
| 10688091 | 2035-08-17 | DP | |
| 10849894 | 2035-08-17 | U-543 | |
| 11154552 | 2035-08-17 | DP | |
Clinical
Clinical Trials
448 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 22 | 24 | 52 | 79 | 50 | 220 |
| Psychotic disorders | D011618 | — | F20.81 | 4 | 4 | 15 | 34 | 23 | 78 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 4 | 4 | 27 | 25 | 18 | 77 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 4 | 4 | 18 | 23 | 9 | 57 |
| Depression | D003863 | — | F33.9 | 2 | 4 | 20 | 20 | 7 | 52 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | 14 | 15 | 10 | 41 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 3 | 3 | 6 | 15 | 9 | 35 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | — | 3 | 7 | 5 | 3 | 18 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 1 | 5 | 7 | 13 |
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | — | 1 | 7 | 2 | 2 | 12 |
Show 65 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Developmental disabilities | D002658 | EFO_0003852 | F89 | — | 2 | 1 | — | — | 3 |
| Schizophrenia spectrum and other psychotic disorders | D019967 | — | — | — | — | 2 | — | 1 | 3 |
| Behavioral symptoms | D001526 | HP_0000708 | — | — | — | 2 | — | — | 2 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 1 | 1 | — | — | 2 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Drug therapy | D004358 | — | — | — | 1 | 1 | — | — | 1 |
| Shared paranoid disorder | D012753 | — | F24 | — | 1 | 1 | — | — | 1 |
| Disease progression | D018450 | — | — | — | — | 1 | — | — | 1 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | 1 | 1 | — | — | 1 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nervous system diseases | D009422 | — | G00-G99 | 2 | 2 | — | — | 1 | 5 |
| Cocaine-related disorders | D019970 | — | F14 | 2 | 2 | — | — | — | 4 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 1 | — | — | — | 3 |
| Asperger syndrome | D020817 | EFO_0003757 | F84.5 | — | 3 | — | — | — | 3 |
| Trichotillomania | D014256 | HP_0012167 | F63.3 | — | 1 | — | — | 1 | 2 |
| Fragile x syndrome | D005600 | — | Q99.2 | — | 1 | — | — | — | 1 |
| Excoriation disorder | D000096705 | — | — | — | 1 | — | — | — | 1 |
| Impulsive behavior | D007175 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | — | 6 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
| Immunoassay | D007118 | — | — | 1 | — | — | — | — | 1 |
| Central nervous system diseases | D002493 | HP_0002011 | G96.9 | 1 | — | — | — | — | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 1 | — | — | — | — | 1 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | — | — | — | — | 1 | 1 |
| Emergencies | D004630 | — | — | — | — | — | — | 1 | 1 |
| Microvascular angina | D017566 | — | — | — | — | — | — | 1 | 1 |
| Therapeutic equivalency | D013810 | — | — | — | — | — | — | 1 | 1 |
| Conversion disorder | D003291 | — | F44 | — | — | — | — | 1 | 1 |
| Dissociative disorders | D004213 | — | F44.1 | — | — | — | — | 1 | 1 |
| Patient satisfaction | D017060 | — | — | — | — | — | — | 1 | 1 |
| Cognition | D003071 | EFO_0003925 | — | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Aripiprazole lauroxil |
| INN | aripiprazole |
| Description | Aripiprazole lauroxil is a dodecanoate ester obtained by formal condensation of the carboxy group of dodecanoic acid with the hydroxy group of 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2H)-yl]methanol. A prodrug for aripiprazole, it is used for treatment of schizophrenia. It has a role as a H1-receptor antagonist, a second generation antipsychotic, a serotonergic agonist and a prodrug. It is a dodecanoate ester, a quinolone, a dichlorobenzene, a N-arylpiperazine, a N-alkylpiperazine, an aromatic ether and a delta-lactam. |
| Classification | Small molecule |
| Drug class | antiulcer agents (benzimidazole derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21 |
Identifiers
| PDB | — |
| CAS-ID | 1259305-29-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2219425 |
| ChEBI ID | — |
| PubChem CID | 49831411 |
| DrugBank | DB14185 |
| UNII ID | 82VFR53I78 (ChemIDplus, GSRS) |
Target
Alternate
HTR1A
HTR1A
HTR2C
HTR2C
HTR6
HTR6
DRD4
DRD4
HTR7
HTR7
HRH1
HRH1
HTR2A
HTR2A
HTR1B
HTR1B
HTR1D
HTR1D
Organism
Homo sapiens
Gene name
HTR1A
Gene synonyms
ADRB2RL1, ADRBRL1
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 1A
Protein synonyms
5-HT1a receptor, 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled, G-21, guanine nucleotide-binding regulatory protein-coupled receptor, Serotonin receptor 1A
Uniprot ID
Mouse ortholog
Htr1a (15550)
5-hydroxytryptamine receptor 1A (Q8BGS4)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Abilify – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Aristada – Alkermes
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,618 documents
View more details
Safety
Black-box Warning
Black-box warning for: Abilify, Abilify abilify, Abilify abilify discmelt, Abilify asimtufii, Abilify maintena, Abilify mycite, Aripiprazole, Aripiprazole oral solution, Aristada, Aristada initio, Opipza
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
91,665 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use